Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03213652CT.gov Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | — | Active Not Recruiting | — | — | — |
NCT03155620CT.gov Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rhabdomyosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ensartinib (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Irinotecan | Milton S. Hershey Medical Center | P2 | BB |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| (+)-Vincristine | Theodore Laetsch | P2 | B |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | B |
| Adriamycin | Children's National Research Institute | P2 | B |
| Vinorelbine Ditartrate | Children's Oncology Group | P3 | B |
+42 more in the Rhabdomyosarcoma cohort
Other indications for Ensartinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | B · 63 |
| Non-Hodgkin Lymphoma | — | P2 | CCC · 53 |
| Langerhans Cell Histiocytosis | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ensartinib in Rhabdomyosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ensartinib-rhabdomyosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →